{"id":587,"date":"2020-10-17T12:03:39","date_gmt":"2020-10-17T12:03:39","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=587"},"modified":"2020-10-17T12:03:39","modified_gmt":"2020-10-17T12:03:39","slug":"13-oct-2020-sarilumab-beneficial-clinical-outcome-and-good-safety","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/13-oct-2020-sarilumab-beneficial-clinical-outcome-and-good-safety\/","title":{"rendered":"(13 Oct 2020) Sarilumab- beneficial clinical outcome and good safety"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\">Sarilumab use in severe SARS-CoV-2 pneumonia<\/p>\n<p>https:\/\/doi.org\/10.1016\/j.eclinm.2020.100553<\/p>\n<p class=\"\">Of the 53 SARS-CoV-2(pos) patients receiving Sarilumab, 39(73.6%) were treated in medical wards [66.7% with a single infusion; median PaO2\/FiO2:146(IQR:120-212)] while 14(26.4%) in ICU [92.6% with a second infusion; median PaO2\/FiO2: 112(IQR:100-141.5)].Within the medical wards, 7(17.9%) required ICU admission, 4 of whom were re-admitted to the ward within 5-8 days. At 19 days median follow-up, 89.7% of medical inpatients significantly improved (46.1% after 24 h, 61.5% after 3 days), 70.6% were discharged from the hospital and 85.7% no longer needed oxygen therapy. Within patients receiving Sarilumab in ICU, 64.2% were discharged from ICU to the ward and 35.8% were still alive at the last follow-up. Overall mortality rate was 5.7%.IL-6R inhibition appears to be a potential treatment strategy for severe SARS-CoV-2 pneumonia and intravenous Sarilumab seems a promising treatment approach showing, in the short term, an important clinical outcome and good safety.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Sarilumab use in severe SARS-CoV-2 pneumonia https:\/\/doi.org\/10.1016\/j.eclinm.2020.100553 Of the 53 SARS-CoV-2(pos) patients receiving Sarilumab, 39(73.6%) were treated in medical wards [66.7% with a single infusion; median PaO2\/FiO2:146(IQR:120-212)] while 14(26.4%) in ICU [92.6% with a second infusion; median PaO2\/FiO2: 112(IQR:100-141.5)].Within the&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/13-oct-2020-sarilumab-beneficial-clinical-outcome-and-good-safety\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(13 Oct 2020) Sarilumab- beneficial clinical outcome and good safety&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[61],"tags":[62],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/587"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=587"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/587\/revisions"}],"predecessor-version":[{"id":588,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/587\/revisions\/588"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=587"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=587"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=587"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}